Mydoma Proteins. CBPCI01 (IgG~ b) myeloma protein was obtained from ascitic fluid of C.B20 mice that bore the CBPC101 myeloma tumor. It was purified on a protein A-Sepharose 4B column (Pharmacia Fine Chemical Co., Div. of Pharmacia, Inc., Piscataway, N. J.). UPC10 and LPC1 (IgG2aa), MOPC195 (IgG2ba), MOPC31C (IgGl"), and UPC61 (IgA a) myeloma proteins were obtained from Dr. M. Potter (National Cancer Institute, National Institutes of Health, Bethesda, Md.).
Products of hybridomas No. 10-3.6, Ig(lb)5.7.1, Ig(lb)3.1, Ig(lb)2.9, and Ig(lb)4.7 were obtained from Dr. V. Oi and Dr. L. Herzenberg (Stanford University, Stanford, Calif.) and S1G.1E and S1A.1A from Dr. M. Bosma (Institute for Cancer Research, Fox Chase, Pa.).
Immunization of Mice.

PREPARATION OF ANTI-lcG~. h ALLOTYPE ANTIBODY IN VARIOUS STRAINS OF MICE.
Anti-allotype antibodies were prepared by immunization of mice with 75 pg of CBPC101 myeloma protein emulsified in complete Freund's adjuvant (CFA). This was followed 5 d later by a similar dose of myeloma protein in incomplete Freund's adjuvant and then by one to six weekly injections of 75 #g of myeloma protein in saline.
PREPARATION OF ANTI-IDIOTYPE (Id) SERUM. BALB/c anti-IgGza b allotype antibodies from an individual mouse and pooled C.AL20, P/J, and DBA/2 anti-IgG2a b allotype antibodies were purified by affinity chromatography on a column of CBPC101-Sepharose 4B according to a previously described technique (10) . These purified anti-allotype antibodies were coupled to keyhole limpet hemocyanin (KLH) at a 1:1 ratio as previously described (10) . BAB. 14, CXBI, and B.C8 mice were immunized with the anti-allotype-KLH conjugate according to the same schedule as that used to raise anti-allotype antibodies. These antisera were made specific for Id by adsorption with BALB/c, BALB.B, P/J, C.AL20, or DBA/2 immunoglobulins as described by Lieberman and Humphrey (8) .
Coating of Sheep Erythrocytes (SRBC). SRBC were coated with myeloma proteins, with
purified BALB/c, C.AL20, P/J, and DBA/2 anti-CBPC 101 antibodies and with C57BL/6 Ig by the chromic chloride method using a concentration of 1 mg/ml of the appropriate protein (6) .
Determination of Hemagglutinin (HA) Titers. HA titers of antibodies specific for IgG2a b allotypic determinants were measured in microtiter plates using SRBC that were coated with CBPC101 or C57BL/6 Ig. The titer of anti-class or anti-allotype antibodies specific for Igh-C determinants of the a allotypic form was determined using UPC10, MOPC195, MOPC31C, and UPC61-coated SRBC. In each case, the titer recorded is 1/log2 of the highest dilution of antisera that caused agglutination.
Determination of Serum IdX Titer.
A hemagglutination-inhibition (HI) method described previouslyb(2 ) was used to test sera for Id. In these experiments, specifically purified BALB/c anti-IgGh antibodies were coupled to SRBC. The capacity of various sera to inhibit agglutination of these cells by BAB.14, CXBI, or B.C8 anti-(BALB/c anti-IgG2a b) antibodies was determined. The titer reported is 1/log2 of the highest dilution that caused inhibition of hemagglutination.
Radioimmunoassay. Purified BALB/c, C.AL20, P/J, and DBA/2 anti-IgG2a b antibodies were tritiated according to a technique described by Wilder et al. (11) . The specific activity was ~0.05 pCi//~g protein.
The ability of 3H-BALB/e, -C.AL20, -P/J, and -DBA/2 anti-IgG~ b antibodies to be bound by BAB.14, CXBI, or B.C8 anti-Id antisera was determined as follows: Microtiter plates were coated with various dilutions of anti-Id antisera by overnight incubation followed by three washings with saline. The plates were then incubated with 50% fetal calf serum (FCS) in saline. After three washings with saline, they were incubated with 3H-anti-IgG2a b for 3 h. The plates were then exhaustively washed and dried. Radioactivity on plates was measured in a liquid scintillation spectrometer (Beckman Instruments, Inc., Fullerton, Calif.). To determine the capacity of various anti-IgGh b antisera to inhibit the binding of 3H-anti-IgG2~ b by anti-Id antibodies, plates that were already coated with BAB.14, CXBI, or B.C8 antisera were incubated for at least 3 h with various dilutions of the inhibitory sera prior to the addition of aH-antibodies.
Isoelectric Focusing. Anti-IgG2~ b antisera were analyzed by isoelectric focusing according to a previously described technique (12) . Gels were overlaid with a 12SI-labeled Fc fragment of CBPC101 myeloma protein, kindly donated by Dr. M. Stanislavsky, Centre National de Recherche Scientifique, Villejuif, France.
Results
Genetic Control of Production of Anti-Allotype (IgG2a b) Antibody. Various strains of mice were injected with CBPC 101 myeloma protein, and the titer of anti-allotype antibody was determined by HA assay. In those cases in which sera agglutinated CBPC101-and C57BL/6-Ig-coated SRBC at a similar dilution, we concluded that anti-allotype antibody was present, whereas for those cases in which the sera agglutinated CBPC101-coated SRBC but not C57BL/6-Ig-coated SRBC, we concluded that antibodies specific for the Id of the CBPC101 myeloma protein (anti-Id CBPCI01) were present.
Mice of the d (i.e., BALB/c, DBA/2, and C.AL20), r (i.e., RIII), p (i.e., P/J), q (i.e., DBA/1J), and s (i.e., SJA) haplotypes made very strong anti-allotype antibody responses as a result of immunization with CBPC101. Among mice of the b type, BALB.B., B.C8, CXBJ, and CXBG made strong responses; however, only one of five 129/SV mice made anti-allotype antibody, whereas two mice made only anti-Id CBPC101 antibody. Mice of the k (i.e., CBA/J, CBA/N, BALB.K, C3H/HeN, CE/ J, c58/j, and AKR), m (i.e., AKR.M), a (i.e., A/He), a I (i.e., AL/N), u (i.e., PL/J), and z (i.e., NZW/J) haplotypes made no, or only a very poor, response (Table I) . It should be noted that the HA titer of CBA/N serum probably does not represent antiallotype antibody because this serum agglutinates UPC-10 (IgG2aa)-coated SRBC to the same extent as it agglutinates CBPC101-coated SRBC.
The importance of MHC genes in this response is shown by the fact that an excellent correlation between MHC type and anti-allotype response exists. Furthermore, among a series of congenic strains, including BALB/c (H-2a), BALB.B (H-2b), and BALB.K (H-2k), the H-2 d and H-2 b strains respond, although the H-2 k strain does not. Although these results indicate that the critical genes are within the MHC, they do not map such genes more precisely. We have been unable, thus far, to carry out intra-MHC mapping largely because strains which themselves possess IgG2a b (e.g., C57BL/10) do not make anti-allotype antibody to CBPC101; thus, the B10 recombinant series cannot be employed for mapping.
Characterization of Anti-Id Antibodies Against BALB/c Anti-Allotype (IgG2a b) Antibodies. BAB.14 and CXBI mice were immunized with affinity chromatographypurified anti-CBPC101 antibodies coupled to KLH. The anti-CBPCl01 antibodies used for immunization originated from a single BALB/c mouse. Four BAB.14 and three CXBI mice developed high-titered antibodies which agglutinated SRBC to which BALB/c anti-CBPC 101 antibodies had been coupled. These sera were pooled and found to have little or no activity against SRBC coupled with UPC10 (IgGza~), MOPC195 (IgG2ba), MOPC31C (IgGl~), and UPC61 (IgAa). The agglutination titer of the pool of BAB. 14 antisera for SRBC coupled with BALB/C anti-CBPC101 antibody was 2.6 × 10 ~, whereas that of CXBI pooled serum was 1.3 × 10 ~ (Table II) . Furthermore, BAB. 14 and CXBI normal sera, BAB. 14 anti-(BALB/c anti-ovalbumin [Ova]) serum, CBPC101 (10 mg/ml), and C57BL/6 Ig (2 mg/ml) caused little or no agglutination of SRBC that were coated with purified BALB/c anti-CBPC101 antibody. Thus, the ability of anti-(BALB/c anti-CBPC101) antibody to cause agglutination of anti-CBPC101-coated erythrocytes cannot be explained by the binding of anti-CBPC 101 to IgG2a b in the agglutinating sera. Rather, it must represent the activity of anti-Id antibody in the CXBI and BAB.14 anti-(BALB/c anti-CBPC 101) antisera. Anti-Id antibodies against anti-IgG2a b allotype antibodies were also obtained in B.C8 mice by immunization with BALB/c anti-CBPC101 antibodies. B.C8 mice possess the BALB/c(a) form of IgG2a. Anti-Id antibodies were also obtained in B.C8 mice immunized with purified C.AL20, P/J, and DBA/2 anti-CBPC101 antibodies (Table III) . The titer of anti-Id antibodies obtained in BAB. 14 and CXBI mice was normal BAB. 14 serum and by BAB. 14 antiserum specific for the Id of BALB/c antiOva antibody, as expected, because these sera contain IgG2a b molecules. However, the binding of 3H-BALB/c anti-allotype antibody to BAB.14 anti-(BALB/c anti-CBPC 101) antibody was substantially greater than that of the control sera and could be observed at a 10 -G dilution; at such a dilution, the control sera had no binding activity. The 3H-BALB/c anti-CBPC 101 antibodies were significantly bound by B.C8 anti-Id serum but not by normal B.C8 serum (Fig. 1 A) . The aH-C.AL20 and DBA/ 2 anti-CBPC 101 antibodies were not significantly bound by BAB. 14 and B.C8 normal sera but were strongly bound to BAB.14 and B.C8 anti-Id sera ( Fig. 1 B and D) . The 3H-P/J anti-CBPC101 antibodies were significantly bound to BAB. 14 normal serum diluted 10 -2. However, the binding of these labeled antibodies by BAB. 14 and B.C8 anti-Id antisera was significantly higher than that of corresponding normal sera at all dilutions (Fig. 1 C) . These results indicate that immunization of BAB.14, CXBI, or B.C8 mice with purified anti-CBPC101 allotype antibody led to the production of antisera that contained antibodies against Id determinants of BALB/c, C.AL20, P/J, and DBA/2 anti-IgG2a b allotype antibodies. Preincubation of aH-anti-CBPC101 antibody with unlabeled anti-CBPC 101 or with the Fc fragment of CBPC 101 strongly inhibited the subsequent binding of 3H-antibody to both BAB. 14 and B.C8 anti-Id antisera coated on microtiter plates (Table IV) binding of anti-Id antibody in HA and RIA tests to determine whether the Id expressed on the anti-allotype antibodies of the individual BALB/c mouse used to produce BAB. 14 and CXBI anti-Id antibodies was also expressed on the anti-allotype antibodies of other BALB/c mice. As can be seen in Table V , all nine BALB/c mice produced a high titer of anti-allotype antibodies. Sera of each of these mice inhibited binding of CXBI anti-Id antisera in both HA and RIA tests. With BAB.14 anti-Id serum, six of the nine individuals showed a substantial inhibitory titer in RIA, although less than they had exhibited with the CXBI anti-Id antibody. These results suggest that idiotypic determinants were shared by anti-allotype antibodies produced in various individual BALB/c mice.
HA Titer of Anti-ld Sera Raised in Various Strains of Mice Immunized with Purified Anti-CBPC I O I Antibody
Anti-CBPC101 antisera from 12 responder strains of mice were tested for the presence of IdX by determining their ability to inhibit the reaction between B.C8 and BAB. 14 anti-Id sera and SRBC that were coated with BALB/c anti-CBPC 101 (Table  VI) . Anti-allotype antisera from each of these strains inhibited hemagglutination indicating the sharing of IdX by their anti-allotype antibodies. Similar results were obtained by RIA using 3H-BALB/c anti-CBPC101 antibodies and BAB.14 anti-Id antiserm.
In general, mice of the H-2 b type developed lower IdX HI titers than did mice of other responder MHC types. The expression of IdX on anti-allotype antibody was observed in mice of each 1gh-C type tested; this included the a, c, g, h, and o types. We could not determine the capacity of mice of the b lgh-C type to produce IdX because these mice possess IgG~ b and thus do not produce anti-allotype antibodies upon immunization with CBPC101.
The IdX was not expressed on a goat anti-IgG2a b anti-allotype antibody which was raised by immunization with the Fc fragment of CBPCI01. Similarly, sera which were principally specific for idiotypic determinants of CBPC 101 raised in responder * SRBC were coated with specifidally purified BALB/c anti-CBPC 101 antibodies. $ Plates were coated with a 1:50,00 dilution of either BAB.14 or CXBI anti-(BALB/c anti-CBPCl01) and incubated with the following dilutions of anti-CBPCl01 antisera from individual BALB/c mice: 1:3, 1:10, 1:30, 1:100, 1:300, and 1:1,000. The capacity of aH-BALB/c anti-CBPC 101 antibodies to bind to the plate was then tested. Results are expressed as l/highest dilution of serum causing >50% inhibition of binding. strains (e.g., 129, CXBJ, BALB.B, and DBA/1) and in nonresponder strains lacked the IdX as tested by HA assay and by RIA. Through the kindness of Dr. Vernon Oi, Dr. Leonard Herzenberg, and Dr. Melvin Bosma, we had the opportunity to study the expression of IdX on monoclonal antiIgG2a b anti-allotype antibodies obtained from fusion of lymphocytes of BALB/c or SJA mice immunized with CBPC101. Each of these hybridoma products is specific for allotypic determinants of CBPC101. In four cases, more precise specificity assignments have been made. Both IG(lb)5.7.1 and Ig(lb)3.1 appear to identify CH3 domain determinants, whereas Ig(lb)2.9 has been assigned a CH2 domain specificity and Ig(lb)4.7, a hinge-region specificity (13) . Each of the hybridoma antibodies, with the exception of Ig(lb)4.7, expressed a substantial HA titer for CBPC 101 and C57BL/6-Ig-coated SRBC (Table VII) . All of the HA-positive hybridoma antibodies inhibited the binding of BAB. 14 anti-Id sera to anti-CBPC 101 antibody, although the inhibitory titer depended both on the hybridoma and the strain of origin of the anti-allotype antibody (Table VIII) . Furthermore, the two hybridomas specific for the Cna domain and the one reagent specific for the CH2 domain of IgGza b each inhibited, at a dilution of 1:30, >85% of the binding BAB. 14 anti-Id sera to 3H-purified BALB/c anti-CBPC 101 antibody, indicating extensive idiotypic sharing between these hybridoma products despite their distinctive specificities.
Overall, these data showed that an IdX or a family of IdX expressed by an anti-I b .... ( gGz, )-allotype antibody originating from one individual BALB/c mouse or pools of C.AL20, P/J, and DBA/2 anti-allotype sera are also expressed on anti-allotype antibodies of various BALB/c individuals. Furthermore, this IdX was found on antiallotype antibodies produced in various strains of mice as well as on products of Results are reported as 1/greatest dilution of hybridoma product which gave >50% inhibition of binding of SH-anti-allotype antibody to plates coated with a 1:50,000 dilution of BAB. 14 anti-(BALB/c anti-CBPC 101) antiserum. Dilutions tested were 1:3, 1 : 10, 1:30, 1 : 100, 1:300, 1 : 1,000, and 1:3,000. § ND, not done.
hybridomas. The relatedness of the anti-allotype antibodies was further tested by studying the ability of anti-Id sera produced in BAB.14, CXBI, and B.C8 to agglutinate SRBC that were coated with BALB/c, C.AL20, P/J, and DBA/2 anti-CBPC101-purified antibody. The results presented in Table IX show that anti-Id antibodies raised against BALB/c, BALB.B, DBA/2, P/J, and C.AL20 anti-CBPC 101 antibodies each interacted, with two exceptions, with BALB/c, DBA/2, P/J, and C.AL20 anti-IgG2a b allotype antibodies. These observations provide further support for the conclusion that anti-IgG2a b antibodies produced in various strains express a substantial degree of idiotypic similarity.
Isoelectric Focusing Pattern of Anti-Allotype Antibodies. Anti-CBPC101 antibodies produced by a variety of responding strains showed strikingly similar isoelectric focusing patterns when tested for their ability to bind 125I-Fc fragments of CBPC 101 myeloma protein (Fig. 2) . The anti-CBPC 101 sera of some strains (B.C8, 129, and DBA/2) did differ from other strains in that they lacked antibodies which focused in basic regions of the gel. However, the Fc CBPC101-binding antibodies found in these strains were Mice of each of the responder MHC haplotypes make anti-allotype antibodies which express IdX determinants found on BALB/c, C.AL20, P/J, and DBA/2 anti-CBPC 101 antibodies and identified by BAB. 14, CXBI, and B.C8 anti-Id antibodies. Study of these antibodies by isoelectric focusing indicates that the anti-allotype antibody response is of limited heterogeneity.
The expression of an IdX by anti-immunoglobulin antibodies extends the observations of Kunkel et al. (14) that monoclonal human IgM proteins specific for IgG share an IdX and that the light (L) chains of these proteins demonstrate a striking restriction of Ig L-chain variable region (Igl-V) subgroup (15) .
The IdX identified on anti-CBPC101 antibodies are expressed on five of six antiIgG2a b hybridoma products. These IdX + hybridomas are of the IgGl, IgGz~, and IgGa classes, indicating that the expression of the IdX is not limited to Ig of a single class. Furthermore, of the IdX + hybridomas, two are specific for a Cna-domain determinant and one for a CH2 determinant (13) . This demonstration that IdX are expressed on antibodies of apparently different specificities has clear precedence in the work of Oudin and Cazenave on expression of idiotypic determinants on antibodies to distinct fragments of fibrinogen (16) and on sharing of Id by anti-Ova antibodies and by Ig that lacks Ova specificity (17) . Similarly, Eichmann et al. (18) have reported that the A5A idiotype is expressed on both anti-streptococcus A carbohydrate antibody and on Ig molecules that are not specific for such determinants. It is a provocative finding that in o u r studies a n d that o f C a z e n a v e a n d O u d i n (16), a n t i b o d i e s to distinct d e t e r m i n a n t s on the s a m e m o l e c u l e share idiotypic d e t e r m i n a n t s . T h e o b s e r v a t i o n that the I d X o f the anti-IgGz, b a n t i b o d i e s are associated w i t h the c o m b i n i n g site reinforces the interest o f this finding. Possible e x p l a n a t i o n s for such idiotypic s h a r i n g by antibodies r e c o g n i z i n g distinct specificities on the s a m e m o l e c u l e is that the V-region gene for one antibody arose by somatic mutation from the gene for the other (or from a common precursor) and that the presence of antigen selectively stimulated the mutant clone. Alternatively, T lymphocytes or antibody specific for the IdX, generated in response to one determinant on the molecule, may have been indirectly focused upon B lymphocytes specific for other determinants on the same molecule and thus favored the stimulation of IdX + clones specific for any determinant on the antigen used for immunization.
The expression of IdX on anti-allotype antibodies has been found in mice of all with the CBPC101 myeloma protein (IgG~b), whereas mice of the k, m, a, 01, u, and z haplotypes made no, or a very poor, response.
All responder strains produce anti-IgG~ b antibodies which share common idiotypes (Id) without relation to the allelic forms of the Ig heavy-chain-constant region genes that the responding mice possess. Isoelectric focusing analysis of the anti-allotype antibodies produced in various strains of mice showed that they are of limited heterogeneity and quite similar from strain to strain. Five out of six hybridoma products with specificity for CBPC101 allotype expressed cross-reactive idiotypes (IdX). Two ofhybridoma products expressing IdX identify Can-domain determinants, and one has been assigned a Cm-domain specificity.
